Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
- Status
- RECRUITING
- Phase
- PHASE2
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
- Status
- COMPLETED
- Phase
- PHASE3
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
A Study of Olaparib and Durvalumab in Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
- Status
- COMPLETED
- Phase
- PHASE1
AMTEC IIT: Phase 2 Multiarm Study in TNBC
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1